Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keri Anti-Bacterial Hand Lotion prophylaxis claims cited in FDA warning letter.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL KERI ANTI-BACTERIAL LOTION PROPHYLACTIC CLAIMS DRAW WARNING LETTER from FDA citing the antibacterial hand lotion as an unapproved new drug that may not be marketed in the U.S. without an approved NDA. Preventative indications for Bristol- Myers Squibb's Keri Anti-Bacterial Hand Lotion "do not qualify for evaluation under the ongoing OTC drug review being conducted by the FDA," the May 8 warning letter states. According to the agency, the product is intended for "repeated use on the hands by the general public and by health care professionals as an antiseptic/moisturizer and to remain on the skin to provide hours of continuous antimicrobial effectiveness against pathogenic microorganisms."
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS088539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel